Neovacs Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Neovacs has been growing earnings at an average annual rate of 6.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 40.6% per year.
Información clave
6.6%
Tasa de crecimiento de los beneficios
100.0%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 30.8% |
Tasa de crecimiento de los ingresos | 40.6% |
Rentabilidad financiera | -17.9% |
Margen neto | -1,639.2% |
Última actualización de beneficios | 31 Dec 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Neovacs. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Dec 23 | 1 | -9 | 3 | 0 |
30 Sep 23 | 0 | -7 | 3 | 0 |
30 Jun 23 | 0 | -5 | 3 | 0 |
31 Mar 23 | 0 | -4 | 3 | 0 |
31 Dec 22 | 0 | -4 | 3 | 0 |
30 Sep 22 | 0 | -8 | 3 | 0 |
30 Jun 22 | 0 | -11 | 3 | 0 |
31 Mar 22 | 0 | -12 | 3 | 0 |
31 Dec 21 | 0 | -12 | 3 | 0 |
30 Sep 21 | 0 | -7 | 3 | 0 |
30 Jun 21 | 0 | -3 | 2 | 0 |
31 Mar 21 | 0 | -5 | 2 | 0 |
31 Dec 20 | 0 | -6 | 2 | 0 |
30 Sep 20 | 0 | -8 | 2 | 0 |
30 Jun 20 | 0 | -10 | 2 | 0 |
31 Mar 20 | 0 | -9 | 2 | 0 |
31 Dec 19 | 0 | -8 | 3 | 0 |
30 Sep 19 | 0 | -8 | 3 | 0 |
30 Jun 19 | 0 | -8 | 3 | 0 |
31 Mar 19 | 0 | -10 | 3 | 0 |
31 Dec 18 | 0 | -11 | 3 | 0 |
30 Sep 18 | 0 | -12 | 3 | 0 |
30 Jun 18 | 0 | -13 | 3 | 0 |
31 Mar 18 | 0 | -14 | 3 | 0 |
31 Dec 17 | 0 | -15 | 3 | 0 |
30 Sep 17 | 0 | -15 | 3 | 0 |
30 Jun 17 | 0 | -15 | 3 | 0 |
31 Mar 17 | 0 | -15 | 3 | 0 |
31 Dec 16 | 0 | -14 | 3 | 0 |
30 Sep 16 | 1 | -10 | 3 | 0 |
30 Jun 16 | 1 | -7 | 3 | 0 |
31 Mar 16 | 1 | -6 | 2 | 0 |
31 Dec 15 | 1 | -5 | 2 | 0 |
30 Sep 15 | 1 | -7 | 2 | 0 |
30 Jun 15 | 0 | -9 | 2 | 0 |
31 Mar 15 | 0 | -8 | 2 | 0 |
31 Dec 14 | 0 | -8 | 2 | 0 |
30 Sep 14 | 0 | -7 | 2 | 0 |
30 Jun 14 | 0 | -7 | 2 | 0 |
31 Mar 14 | 0 | -7 | 2 | 0 |
31 Dec 13 | 0 | -7 | 3 | 0 |
Ingresos de calidad: ALNEV is currently unprofitable.
Margen de beneficios creciente: ALNEV is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ALNEV is unprofitable, but has reduced losses over the past 5 years at a rate of 6.6% per year.
Acelerando crecimiento: Unable to compare ALNEV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ALNEV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rentabilidad financiera
Alta ROE: ALNEV has a negative Return on Equity (-17.9%), as it is currently unprofitable.